More Cost Cuts At Pfizer Bring Total Savings To $5.5bn

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

A new round of cost-cutting at Pfizer will deliver savings of $1.5bn by the end of 2027, the company reported in an SEC filing.

Albert Bourla
Pfizer announced $1.5bn more in cost cuts • Source: Shutterstock

Pfizer Inc. revealed that more cost cutting is in store for the big pharma on top of cost reduction programs already underway. The company revealed the latest cuts in a filing with the Securities & Exchange Commission on 22 May, announcing plans to deliver $1.5bn in annual savings by the end of 2027.

Key Takeaways

  • Pfizer announced a new round of cost cutting aimed at delivering $1.5bn in savings by 2027.

The effort, focused on reducing the cost of goods sold, will be a multi-year program, however, with the latest announcement...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains